Merck Inks Deal For Generic Fosamax: Report
With its main patent for Fosamax set to expire in February, Merck & Co. has reportedly struck an authorized generic deal with an anonymous company to market a generic copy of...To view the full article, register now.
Already a subscriber? Click here to view full article